TECregen Strengthens Management Team and Board to Advance Thymus Regeneration and Lead Program TEC001
Elisabeth Svanberg, MD, PhD, appointed Chief Medical Officer, adding extensive global clinical–development and regulatory expertise Thomas Hanke, PhD, joins the Board, bringing more than 30 years of immunology, drug–discovery, and R&D experience Appointments strengthen TECregen as it advances TEC001 toward clinical development Basel, Switzerland, November 10, 2026 – TECregen, a biotechnology company pioneering thymus regeneration […]




